The role of Anti-PD-1/PD-L1 monotherapy as first-line treatment of metastatic NSCLC without targetable mutations and PD-L1 TPS 1–49% Arpeet T. Shah, Joel W. Neal PDF COI Form
Concerns and controversies regarding ipilimumab-based immunotherapy in the first-line treatment of non-small cell lung cancer Ivy Riano, Narjust Duma PDF COI Form
Management of acquired resistance to ALK inhibitors: repeat biopsy to characterize mechanisms of resistance does not significantly impact clinical outcomes Naiyarat Prasongsook, Thanyanan Reungwetwattana PDF COI Form
